ER-Negative Breast Cancer Is Highly Responsive to Cholesterol Metabolite Signalling.
Ontology highlight
ABSTRACT: Interventions that alter cholesterol have differential impacts on hormone receptor positive- and negative-breast cancer risk and prognosis. This implies differential regulation or response to cholesterol within different breast cancer subtypes. We evaluated differences in side-chain hydroxycholesterol and liver X nuclear receptor signalling between Oestrogen Receptor (ER)-positive and ER-negative breast cancers and cell lines. Cell line models of ER-positive and ER-negative disease were treated with Liver X Receptor (LXR) ligands and transcriptional activity assessed using luciferase reporters, qPCR and MTT. Publicly available datasets were mined to identify differences between ER-negative and ER-positive tumours and siRNA was used to suppress candidate regulators. Compared to ER-positive
SUBMITTER: Hutchinson SA
PROVIDER: S-EPMC6893441 | biostudies-literature | 2019 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA